Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Head and Neck Cancers
•
Radiation Oncology
Does the extent of ENE affect your recommendation for concurrent chemotherapy in HPV+ OPSCC patients planned for adjuvant RT?
Does the ENE of 1 mm or less versus >1 mm as in ECOG 3311 affect your decision?
Answer from: Radiation Oncologist at Academic Institution
I'm wary of de-escalating treatment without phase 3 data supporting that decision. So any ECE, I treat with 66 Gy and concurrent chemo.
Sign In
or
Register
to read more
19938
Related Questions
What dose and treatment area of radiation should be given when p16+/HPV ISH negative SCC is found in the scar of a level V lymph node excisional biopsy with all other workup negative?
Is there a scenario in which you would consider observation for T4a SCC involving the mandible?
What are fractionation options for a patient with progressive jugular foramen paraganglioma now causing multiple cranial nerve deficits?
What alternatives do you recommend for oral dexamethasone solution for HN cancer?
How would you counsel a patient concerned about receiving IMRT rather than IMPT for oropharyngeal cancer?
What's the role of contralateral neck re-irradiation in the post-op setting for someone with a remote history of head and neck cancer who underwent definitive RT with elective dose to the bilateral neck now with a new primary s/p surgery with ipsilateral neck dissection requiring post op chemo radiation for bony involvement and ENE?
In p16-positive oropharyngeal squamous cell carcinoma, when induction therapy is considered before definitive chemoradiation, how do you choose between a traditional TPF regimen and carboplatin/paclitaxel/pembrolizumab?
What are your top takeaways in Head & Neck Cancers from ASCO 2025?
How would you approach post-op radiation recommendations in patients who had neoadjuvant chemoimmunotherapy for HPV mediated OPSCC s/p TORS who have a complete pathologic response (pCR)?
How would you approach a patient treated for a stage I glottic cancer 2 years prior with a biopsy proven recurrence who is declining surgery and any systemic therapy?